The risk of chronic kidney disease, as well as other "silent killers" – diabetes, hypertension, cancer, is that patients for a long time do not experience changes in well-being, leading to late detection of chronic kidney disease, the renal protection therapy has been exhausted. The peculiarity of the problem of chronic kidney disease is the predominance of secondary nephropathies, in connection with patients for a long period of time, there are therapists and specialists –"mineralogie", and the cases of chronic kidney disease as secondary diseases are almost not included in official statistics. The concept of chronic kidney disease does not contradict the priority of the nosological approach in modern medicine. On the contrary, it is intended to provide timely referral of patients with signs of kidney damage to the nephrologist, who conducts a differential diagnosis and establishes a nosological diagnosis, assess the risk of progression, determines etiotropic and pathogenetic therapy. At the same time, the value of the philosophy of chronic kidney disease is that it allows even in the case when the nosological diagnosis is still not fully installed, to plan and carry out activities of secondary prevention, acting on the universal mechanisms of progression of chronic kidney disease to preserve renal function and reduce the risk of cardiovascular complications. Population-based epidemiological studies conducted in the last decade give an idea of the magnitude of the problem of chronic kidney disease. The results of a study of prognosis of chronic kidney disease (Chronic Kidney Disease Prognosis Consortium) showed a significant and independent relationship of estimated GFR and albuminuria with total and cardiovascular mortality, progression of chronic kidney disease and the risk of developing acute kidney injury. Chronic kidney disease is recognized as an independent risk factor for cardiovascular disease and an equivalent of coronary heart disease risk of cardiovascular complications. No doubt the value of microalbuminuria as one of the most important markers of high risk of developing cardiovascular disease and kidney failure. The prevalence of chronic kidney disease is high and is not inferior to the prevalence of such socially significant diseases as diabetes, hypertension, heart failure. In the UK automated screening 10 975 patient records observed by General practitioners revealed 492 cases of chronic kidney disease with GFR < 60 ml/min/1.73 m2 (5.7%). According to the studies conducted on different continents in countries with different ethnic composition and economic development, the signs of chronic kidney disease have been reported in 12-18% of the population, and most adverse chronic kidney disease stages 3-5 – have a 5.9-8.1% of residents (in Japan, to 18.7%). We can assume that every tenth inhabitant of the Earth has signs of chronic kidney disease. Information about nosological composition of the chronic kidney disease require clarification, because population studies usually do not involve a detailed nephrological examinations, and created by currently the registers do not include chronic kidney disease patients in the early stages. In addition, there are differences between countries in the prevalence of renal diseases of different nature (high frequency of urolithiasis in countries of the Middle East, IgA nephropathy in Japan, kidney disease of an infectious nature in developing countries, etc.).

Keywords: chronic kidney disease, prevalence, cardiovascular disease

Full text: PDF (Rus) 303K

1. Shvetsov MYu. Khronicheskaya bolezn pochek kak obshchemeditsinskaya problema: sovremennye printsipy nefroprofilaktiki i nefroprotektivnoy terapii. Consilium medicum. 2014; 16 (7): 51-64. [Russian]
2. Singh AK, Farag YM, Mittal BV, Subramanian KK, Reddy SR, Acharya VN, Almeida AF, Channakeshavamurthy A, et al. Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study BMC. Nephrology. 2013; 14 (1): 114-22. https://www.ncbi.nlm.nih.gov/pubmed/23714169. https://www.ncbi.nlm.nih.gov/pmc/articles/3848478. https://doi.org/10.1186/1471-2369-14-114
3. CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements. 2013; 3 (1): 1-150.
4. Shestakova MV, Shamkhalova MSh, Yarek-Martynova IYa, Sukhareva OYu, i dr. Federalnye klinicheskie rekomendatsii po diagnostike, skriningu, profilaktike i lecheniyu khronicheskoy bolezni pochek u bolnykh sakharnym diabetom. Predstavleny v 2014 g. na II Vserossiĭskom kongresse
s uchastiem stran SNG «Innovatsionnye tekhnologii v endokrinologii». Utverzhdeny na VII Vserossiĭskom diabetologicheskom kongresse "Sakharnyĭ diabet v XXI veke - vremya obedineniya usiliĭ",
24-28 fevralya 2015. Moskva, 2015. 39 s. [Russian]
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39 (2): S1-266. https://www.ncbi.nlm.nih.gov/pubmed/11904577
6. Natsionalnye rekomendatsii. Khronicheskaya bolezn pochek: osnovnye printsipy skrininga, diagnostiki, profilaktiki i podkhody k lecheniyu. Pod red AV Smirnova. Nefrologiya. 2012; 16 (1): 15-89. [Russian]
7. Natsionalnye rekomendatsii. Serdechno-sosudistyy risk i khronicheskaya bolezn pochek: strategii kardionefroprotektsii. Pod red VS Moiseeva, NA Mukhina, AV Smirnova. Rossiĭskiĭ kardiologicheskiĭ zhurnal. 2014; 8 (112): 7–37.
 [Russian]
8. US Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. MD Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013. Available from: https://www.usrds.org/atlas13.aspx
9. Azərbaycan Respublikası Endokrinologiya, Diabetologiya və Terapevnik Təlimat assosiasiyası. Şəkərli diabetin diaqnostikası, profilaktikası və tibbi yardım üzrə standartları. Bakı: “Azərdiab” nəşriyatı, 2015. 150 s. [Azerbaijani]
10. WHO-FIC Network at the annual meeting in Trieste, October 2007. Available from: http://www.who.int/ 27. classifications/icd/ICD-10%20Updates%202007.pdf 

11. Chronic Kidney Disease Prognosis Consortium. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375 (9731): 2073–81. https://www.ncbi.nlm.nih.gov/pubmed/20483451. https://www.ncbi.nlm.nih.gov/pmc/articles/3993088. https://doi.org/10.1016/S0140-6736(10)60674-5
12. Ronco C, McCullough P, Anker S, Anand I, Aspromonte N, Bagshaw SM, Bellomo R, et al. Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J. 2010; 31 (6): 703–11. https://www.ncbi.nlm.nih.gov/pmc/articles/2838681. 10.1093/eurheartj/ehp507
13. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359: 2417–28. https://www.ncbi.nlm.nih.gov/pubmed/19052124. https://doi.org/10.1056/NEJMoa0806182
14. Bakris GL, Seraëdis PA, Weir MR, Dahlof B, et al. Renal outcomes with different ëxed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of randomized controlled trial. Lancet. 2010; 375: 1173–81. 
 https://doi.org/10.1016/S0140-6736(09)62100-0
15. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes 34. mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007; 370: 829–40. 
 https://www.ncbi.nlm.nih.gov/pubmed/17765963. https://doi.org/10.1016/S0140-6736(07)61303-8
16. de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, Neal B, Poulter N, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009; 20: 883–92. https://www.ncbi.nlm.nih.gov/pmc/articles/2663832. https://doi.org/10.1681/ASN.2008070667
17. Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, et al. Cardiorenal endpoints in a trial of Aliskiren for type 2 diabetes. N Engl J Med. 2012; 367: 2204–13. https://www.ncbi.nlm.nih.gov/pubmed/23121378. https://doi.org/10.1056/NEJMoa1208799
18. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012; 367 (24): 2296–304. 
 https://www.ncbi.nlm.nih.gov/pubmed/23131078. https://www.ncbi.nlm.nih.gov/pmc/articles/3690472. https://doi.org/10.1056/NEJMoa1210357
19. Mann JFE, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, et al. Renal outcomes with telmisartan, ramipril,
or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind controlled trial. Lancet. 2008; 372: 547–53. 
 https://www.ncbi.nlm.nih.gov/pubmed/18707986. https://doi.org/10.1016/S0140-6736(08)61236-2
20. Haller H, Ito S, Izzo JL, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, et al. ROADMAP Trial Investigators. Olmesartan for the delay
or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011; 364: 907–17. 
 https://www.ncbi.nlm.nih.gov/pubmed/21388309. https://doi.org/10.1056/NEJMoa1007994
21. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004; 351: 1941-51. https://www.ncbi.nlm.nih.gov/pubmed/15516697. https://doi.org/10.1056/NEJMoa042167
22. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol. 2006; 17: 3472-81. https://www.ncbi.nlm.nih.gov/pubmed/17082240. https://doi.org/10.1681/ASN.2006060560
23. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, Strand T, Drummond K, Donnelly S, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009; 361: 40-51. https://www.ncbi.nlm.nih.gov/pubmed/19571282. https://www.ncbi.nlm.nih.gov/pmc/articles/2978030. https://doi.org/10.1056/NEJMoa0808400
24. Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, Rashkow A, Yusuf S. Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol. 2003; 14: 641-7. https://www.ncbi.nlm.nih.gov/pubmed/12595499. https://doi.org/10.1097/01.ASN.0000051594.21922.99
25. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, et al. The effects of lowering LDL cholesterol with
simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal 
Protection): a randomised placebo-controlled trial. Lancet. 2011; 377 (9784): 2181–92. https://www.ncbi.nlm.nih.gov/pubmed/21663949. https://www.ncbi.nlm.nih.gov/pmc/articles/3145073. https://doi.org/10.1016/S0140-6736(11)60739-3
26. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 41. Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
Kidney Int. 2013; 3 (l): 1–150. 

27. Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int. 2012; 2: 1–138. 

28. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force
for the Management of Arterial Hypertension of the European Society of Hypertension 44. (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34: 2159–219. 
https://www.ncbi.nlm.nih.gov/pubmed/23771844. https://doi.org/10.1093/eurheartj/eht151
29. Natsionalnye rekomendatsii po kardiovaskulyarnoĭ profilaktike. Kardiovaskulyarnaya terapiya i profilaktika. 2011; 10 (6/2): Available from: http:// scardio.ru/rekomendacii/rekomendacii_rko/ 45. 
[Russian]
30. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version
2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies
on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives 46. of nine societies and by invited experts). Eur Heart J. 2012; 33: 1635–701. https://www.ncbi.nlm.nih.gov/pubmed/22555213. https://doi.org/10.1093/eurheartj/ehs092
31. Diagnostika i korrektsiya narusheniĭ lipidnogo obmena s tselyu profilaktiki i lecheniya ateroskleroza. Rossiĭskie rekomendatsii. V peresmotr. Moskva, 2012. Available from: http://cardioline.ru/uploads/Full%20Guidelines.pdf 
[Russian]
32. European Association for Cardiovascular Prevention & Rehabilitation. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32: 1769–818. 
 https://www.ncbi.nlm.nih.gov/pubmed/21712404. https://doi.org/10.1093/eurheartj/ehr158
33. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int. 2013; 3: 259–305. 

34. Antonova TN, Bikbov BT, Gal IG, Tomilina NA. K voprosu o rasprostranennosti khronicheskoy bolezni pochek sredi pozhilykh lits v g. Moskve i ee svyazi s serdechno-sosudistoy patologiey. Nefrologiya i dializ. 2011; 13 (3): 353-4.
 [Russian]
35. Shalyagin YuD. Snizhenie skorosti klubochkovoy filtratsii kak marker khronicheskoy bolezni pochek: chastota vstrechaemosti i klinicheskie assotsiatsii (po dannym obsledovaniya patsientov terapevticheskogo profilya, gospitalizirovannykh v Kolomenskuyu TsRB). Sb tezisov VII Sezda Nauchnogo obshchestva nefrologov Rossii, 19-22 oktyabrya 2010. M, 2010. s 140-1.
 [Russian]
36. Serov VA. Vozrastnye i gendernye osobennosti rasprostranennosti khronicheskoy bolezni pochek sredi bolnykh s khronicheskoy serdechnoy nedostatochnostyu. Nefrologiya i dializ. 2009; 11 (4): 332-5.
 [Russian]
37. Park J. Cardiovascular Risk in Chronic Kidney Disease: Role of the Sympathetic Nervous System. Cardiology Research and Practice. 2012; 2012; 2012: Article ID 319432, 8 pages. https://doi.org/10.1155/2012/319432
38. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375 (9731): 2073–81. https://www.ncbi.nlm.nih.gov/pubmed/20483451. https://www.ncbi.nlm.nih.gov/pmc/articles/3993088. https://doi.org/10.1016/S0140-6736(10)60674-5
39. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney International. 2011; 80 (6): 572–86. https://www.ncbi.nlm.nih.gov/pubmed/21750584. https://doi.org/10.1038/ki.2011.223
40. Green D, Roberts PR, New DI, Kalra PA. Sudden cardiac death in hemodialysis patients: an in-depth review. American Journal of Kidney Diseases. 2011; 57 (6): 921–9. https://www.ncbi.nlm.nih.gov/pubmed/21496983. https://doi.org/10.1053/j.ajkd.2011.02.376
41. Ritz E, McClellan W. Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol. 2004; 15 (3): 513-6. https://www.ncbi.nlm.nih.gov/pubmed/14978152. https://doi.org/10.1097/01.ASN.0000115398.92270.30
42. Vanholder R,Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N; European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial. 2005; 20 (6): 1048-56. https://www.ncbi.nlm.nih.gov/pubmed/15814534. https://doi.org/10.1093/ndt/gfh813
43. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ. The Framingham predictive instrument in chronic kidney disease. J Am Coll Cardiol. 2007; 50 (3): 217-24. https://www.ncbi.nlm.nih.gov/pubmed/17631213. https://doi.org/10.1016/j.jacc.2007.03.037
44. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011; 80 (12): 1258-70.
 https://www.ncbi.nlm.nih.gov/pubmed/21993585. https://doi.org/10.1038/ki.2011.368
45. Hallan SI, Stevens P. Screeningfor chronic kidney disease: which strategy? J Nephrol. 2010; 23 (2): 147-55.
 https://www.ncbi.nlm.nih.gov/pubmed/20155721
46. De Jong PE, van der Velde M, Gansevoort RT, Zoccali C. Screeningfor chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol. 2008; 3 (2): 616-23.
 https://www.ncbi.nlm.nih.gov/pubmed/18287253. https://doi.org/10.2215/CJN.04381007
47. Qaseem A, Hopkins RH Jr, Sweet DE, Starkey M, Shekelle P. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013; 159 (12): 835-47.
 https://www.ncbi.nlm.nih.gov/pubmed/24145991. https://doi.org/10.7326/0003-4819-159-12-201312170-00726
48. Abdel-Kader K. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease. Ann Intern Med. 2014; 161 (1): 83. https://www.ncbi.nlm.nih.gov/pubmed/24979458. https://doi.org/10.7326/L14-5013-4
49. Dhar GC. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease. Ann Intern Med. 2014; 161 (1): 81. https://www.ncbi.nlm.nih.gov/pubmed/24979455. https://doi.org/10.7326/L14-5013
50. Levin A, Stevens PE, Coresh J, Levey A. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease. Ann Intern Med. 2014; 161 (1): 81-2. https://www.ncbi.nlm.nih.gov/pubmed/24979456. https://doi.org/10.7326/L14-5013-2
51. Levin A, Stevens PE. Kidney disease guideline profusion and confusion: unintended consequences of different perspectives and definitions. Am J Kidney Dis. 2014; 63 (5): 749-52. https://www.ncbi.nlm.nih.gov/pubmed/24613054. https://doi.org/10.1053/j.ajkd.2014.02.004
52. Qaseem A, Wilt T, Denberg TD. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease. Ann Intern Med. 2014; 161 (1): 83-4. https://www.ncbi.nlm.nih.gov/pubmed/24979459. https://doi.org/10.7326/L14-5013-5
53. Lambers Heerspink HJ, Gaillard CJ, Gansevoort RT. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease. Ann Intern Med. 2014; 161 (1): 82-3. https://www.ncbi.nlm.nih.gov/pubmed/24979457. https://doi.org/10.7326/L14-5013-3
54. Molitoris BA. Screening: Screening for kidney disease--a lost opportunity. Nat Rev Nephrol. 2014; 10 (1): 6-8. https://www.ncbi.nlm.nih.gov/pubmed/24296624. https://doi.org/10.1038/nrneph.2013.258
55. De Lima AO, Kesrouani S, Gomes RA, Cruz J, Mastroianni-Kirsztajn G. Population screeningfor chronic kidney disease: a survey involving 38,721 Brazilians. Nephrol Dial Transplant. 2012; 27 (3): iii135-8.
56. Nagaytseva SS, Shalyagin YuD, Shvutsov MYu, Pyagay NL, i dr. Otsenka albuminurii metodom test-polosok s tselyu rannego vyyavleniya khronicheskoy bolezni pochek u lits s raznoy stepenyu riska (opyt tsentrov zdorovya Moskovskoy oblasti). Terapevticheskiy arkhiv. 2013; 86 (6): 38-43. [Russian]
57. Anandarajah S, Tai T, de Lusignan S, Stevens P, O'Donoghue D, Walker M, Hilton S. The validity of searching routinely collected general practice computer data to identify patients with chronic kidney disease (CKD): a manual review of 500 medical records. Nephrol Dial Transplant. 2005; 20 (10): 2089-96. https://www.ncbi.nlm.nih.gov/pubmed/16030033. https://doi.org/10.1093/ndt/gfi006
58. Dittmann K, Hannemann A, Wallaschofski H, Rettig R, Stracke S, Völzke H, Nauck M, Friedrich N. U-shaped association between central body fat and the urinary albumin-to-creatinine ratio and microalbuminuria. BMC Nephrology. 2013; 14: 87. https://doi.org/10.1186/1471-2369-14-87
59. Bakris GL, Molitch M. Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga. Diabetes Care. 2014; 37: 867–75. https://www.ncbi.nlm.nih.gov/pubmed/24558077. https://doi.org/10.2337/dc13-1870
60. Pertusa S, Ramos-Lopez C, Martinez-Navas M, Palacios-Marqués A. Moderately increased albuminuria unmasked hypertension. BMJ Case Rep. 2014; 2014: pii: bcr2013202643. https://www.ncbi.nlm.nih.gov/pubmed/25358830. https://www.ncbi.nlm.nih.gov/pmc/articles/4216896. https://doi.org/10.1136/bcr-2013-202643.
61. Pilz S, Rutters F, Nijpels G, Stehouwer CD, Højlund K, Nolan JJ, Balkau B, Dekker JM. Insulin sensitivity and albuminuria: the RISC study. Diabetes Care. 2014; 37 (6): 1597-603. https://www.ncbi.nlm.nih.gov/pubmed/24623021. https://doi.org/10.2337/dc13-2573
62. Jarraya F, Lakhdar R, Kammound K, Mahfoudh H, Drissa H, Kammoun S, Abid M, Hachicha J. Microalbuminuria: a useful marker of cardiovascular disease. Iran J Kidney Dis. 2013; 7 (3): 178-86. https://www.ncbi.nlm.nih.gov/pubmed/23689147